WHO: New coronary pneumonia rehabilitation plasma therapy has not been proven to be effective

Local time on August 24th, WHO held a regular briefing on neo-coronary pneumonia, in response to the United States authorized medical institutions can urgently use the plasma of recovering new coronavirus infection patients to treat new crown inpatients, WHO Chief Scientist Sumia Swaminathan said that rehabilitation plasma therapy has been used for different types of infectious diseases for more than 100 years, for some diseases effective but not effective for other diseases. There have been several clinical trials worldwide for rehabilitation plasma therapy for neo-coronary pneumonia, but only a few have published results, and the results have been mixed, with no consistent conclusions, and the quality of evidence remains low. WHO therefore recommends that rehabilitation plasma therapy continue to be clinically evaluated as an experimental therapy.
Swaminathan also points out that rehabilitation plasma therapy still has some challenges in practice, such as different levels of antibodies carried by people infected with new coronary pneumonia after rehabilitation, which are difficult to standardize. In addition, the number of hospitals that can implement the therapy, as well as the number of donors, is limited, but the most important question is whether the effectiveness and safety of the treatment can be confirmed in randomized trials.
Bruce Aylward, senior adviser to the WHO Director-General, says plasma rehabilitation therapy has many side effects, from chills and fevers to more severe lung damage and even blood circulation overload, so clinical trial results are crucial. (Chief Station Reporter Zhu He)